Literature DB >> 24036111

Phosphorylation and mRNA splicing of collapsin response mediator protein-2 determine inhibition of rho-associated protein kinase (ROCK) II function in carcinoma cell migration and invasion.

Marie Morgan-Fisher1, John R Couchman, Atsuko Yoneda.   

Abstract

The Rho-associated protein kinases (ROCK I and II) are central regulators of important cellular processes such as migration and invasion downstream of the GTP-Rho. Recently, we reported collapsin response mediator protein (CRMP)-2 as an endogenous ROCK II inhibitor. To reveal how the CRMP-2-ROCK II interaction is controlled, we further mapped the ROCK II interaction site of CRMP-2 and examined whether phosphorylation states of CRMP-2 affected the interaction. Here, we show that an N-terminal fragment of the long CRMP-2 splice variant (CRMP-2L) alone binds ROCK II and inhibits colon carcinoma cell migration and invasion. Furthermore, the interaction of CRMP-2 and ROCK II is partially regulated by glycogen synthase kinase (GSK)-3 phosphorylation of CRMP-2, downstream of PI3K. Inhibition of PI3K reduced interaction of CRMP-2 with ROCK II, an effect rescued by simultaneous inhibition of GSK3. Inhibition of PI3K also reduced colocalization of ROCK II and CRMP-2 at the cell periphery in human breast carcinoma cells. Mimicking GSK3 phosphorylation of CRMP-2 significantly reduced CRMP-2 binding of recombinant full-length and catalytic domain of ROCK II. These data implicate GSK3 in the regulation of ROCK II-CRMP-2 interactions. Using phosphorylation-mimetic and -resistant CRMP-2L constructs, it was revealed that phosphorylation of CRMP-2L negatively regulates its inhibitory function in ROCK-dependent haptotactic cell migration, as well as invasion of human colon carcinoma cells. Collectively, the presented data show that CRMP-2-dependent regulation of ROCK II activity is mediated through interaction of the CRMP-2L N terminus with the ROCK II catalytic domain as well as by GSK3-dependent phosphorylation of CRMP-2.

Entities:  

Keywords:  CRMP-2 Phosphorylation; Carcinoma; Cell Invasion; Cell Migration; Collapsin Response Mediator Protein-2; Glycogen Synthase Kinase 3; Protein-serine/threonine Kinase; Rho GTPases; Rho-associated Protein Kinase II

Mesh:

Substances:

Year:  2013        PMID: 24036111      PMCID: PMC3829433          DOI: 10.1074/jbc.M113.505602

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  p90-RSK and Akt may promote rapid phosphorylation/inactivation of glycogen synthase kinase 3 in chemoattractant-stimulated neutrophils.

Authors:  D D De Mesquita; Q Zhan; L Crossley; J A Badwey
Journal:  FEBS Lett       Date:  2001-08-03       Impact factor: 4.124

Review 2.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

3.  RhoE binds to ROCK I and inhibits downstream signaling.

Authors:  Kirsi Riento; Rosa M Guasch; Ritu Garg; Boquan Jin; Anne J Ridley
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 4.  Rho kinase inhibition in diabetic nephropathy.

Authors:  Radko Komers
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-01       Impact factor: 2.894

5.  The structure of human collapsin response mediator protein 2, a regulator of axonal growth.

Authors:  Pål Stenmark; Derek Ogg; Susanne Flodin; Alex Flores; Tetyana Kotenyova; Tomas Nyman; Pär Nordlund; Petri Kursula
Journal:  J Neurochem       Date:  2007-01-22       Impact factor: 5.372

6.  Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease.

Authors:  Yutaka Uchida; Toshio Ohshima; Yukio Sasaki; Hiromi Suzuki; Shigeki Yanai; Naoya Yamashita; Fumio Nakamura; Kohtaro Takei; Yasuo Ihara; Katsuhiko Mikoshiba; Papachan Kolattukudy; Jerome Honnorat; Yoshio Goshima
Journal:  Genes Cells       Date:  2005-02       Impact factor: 1.891

7.  Collapsin response mediator protein-2 (Crmp2) regulates trafficking by linking endocytic regulatory proteins to dynein motors.

Authors:  Juliati Rahajeng; Sai S P Giridharan; Naava Naslavsky; Steve Caplan
Journal:  J Biol Chem       Date:  2010-08-27       Impact factor: 5.157

8.  Rho-associated kinase of chicken gizzard smooth muscle.

Authors:  J Feng; M Ito; Y Kureishi; K Ichikawa; M Amano; N Isaka; K Okawa; A Iwamatsu; K Kaibuchi; D J Hartshorne; T Nakano
Journal:  J Biol Chem       Date:  1999-02-05       Impact factor: 5.157

Review 9.  Regulation of ROCK activity in cancer.

Authors:  Marie Morgan-Fisher; Ulla M Wewer; Atsuko Yoneda
Journal:  J Histochem Cytochem       Date:  2012-11-29       Impact factor: 2.479

10.  The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.

Authors:  Takekazu Kubo; Atsushi Yamaguchi; Nobuyoshi Iwata; Toshihide Yamashita
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

View more
  7 in total

1.  CRMP4a suppresses cell motility by sequestering RhoA activity in prostate cancer cells.

Authors:  Changlin Li; Haixia Xu; Lin Xiao; Haizhou Zhu; Guoan Zhang; Wei Wei; Kaizhi Li; Xiande Cao; Daqing Shen; Jeffrey Holzbeierlein; Benyi Li
Journal:  Cancer Biol Ther       Date:  2018-08-06       Impact factor: 4.742

2.  Impacts of Rho kinase inhibitor Fasudil on Rho/ROCK signaling pathway in rabbits with optic nerve injury.

Authors:  Jianglong Yu; Lin Lin; Xinping Luan; Xiepan Jing
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma.

Authors:  Lin Wang; Weihai Liu; Hengtao Tang; Xianbiao Xie; Changye Zou; Yongqian Wang; Zhenhua Gao; Junqiang Yin
Journal:  Cancer Med       Date:  2017-04-04       Impact factor: 4.452

4.  Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma.

Authors:  Ju Bai; Yun Yang; Jianli Wang; Lei Zhang; Fangxia Wang; Aili He
Journal:  Clin Proteomics       Date:  2019-04-23       Impact factor: 3.988

5.  Valsartan inhibits RhoA-ROCK2-MYL pathway in rat model of alcoholic cardiomyopathy.

Authors:  Luyifei Li; Ling Jing; Jiyi Zhao; Jiachen Lv; Wen Yang; Weimin Li; Lijun Zhou
Journal:  Exp Ther Med       Date:  2019-10-07       Impact factor: 2.447

6.  CRMP2 as a Candidate Target to Interfere with Lung Cancer Cell Migration.

Authors:  Xabier Morales; Rafael Peláez; Saray Garasa; Carlos Ortiz de Solórzano; Ana Rouzaut
Journal:  Biomolecules       Date:  2021-10-18

7.  CRMP2 derived from cancer associated fibroblasts facilitates progression of ovarian cancer via HIF-1α-glycolysis signaling pathway.

Authors:  Yunfeng Jin; Saiyan Bian; Hui Wang; Jiahang Mo; He Fei; Li Li; Tong Chen; Hua Jiang
Journal:  Cell Death Dis       Date:  2022-08-04       Impact factor: 9.685

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.